Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)
Clinical trial NCT04591002 · RECRUITING
Trial details
- NCT number
- NCT04591002
- Sponsor
- Samsung Medical Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-11
- Primary completion
- 2027-09-01
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.